2.50
Hdl Handle:
http://hdl.handle.net/10547/228927
Title:
Pharmaco(epi)genomics in ovarian cancer.
Authors:
Paige, Adam J.W.; Brown, Robert
Abstract:
Ovarian cancer shows considerable variability in its chemoresponse, however, the prospect of individualized medicine holds high hopes for improving patient survival. The influence of interindividual genomic polymorphisms on drug response (pharmacogenomics) is well established, and a variety of candidate loci in ovarian tumors have been identified, including ERCC1, ABCB1 and p53 variants. Recently pharmacoepigenomic modulators of key genes and pathways, such as promoter methylation (MLH1 and BRCA1 genes) and microRNA regulation (PTEN/AKT and NF-kappaB pathways) have been implicated in ovarian cancer chemoresponse. Epigenomic studies have until now mainly focused on tumor-specific changes, although germ-line epigenetic change may also be of importance. However, assessing the relevance of these potential pharmaco(epi)genomic biomarkers in clinical trials requires well powered studies in homogeneous populations, with independent validation sets, to distinguish real associations from false-positives. In addition, the selection of one gene or locus as having sufficient phenotypic effect to impact on clinical outcome may be an oversimplification. Integrated approaches that identify stable pharmacogenomic and epigenomic patterns and their relationship with expression patterns and gene function will be increasingly necessary.
Affiliation:
Department of Oncology, Imperial College, Hammersmith Hospital Campus, London W12 8EE, UK. a.paige@imperial.ac.uk
Citation:
Pharmaco(epi)genomics in ovarian cancer. 2008, 9 (12):1825-1834 Pharmacogenomics
Publisher:
Future Medicine
Journal:
Pharmacogenomics
Issue Date:
Dec-2008
URI:
http://hdl.handle.net/10547/228927
DOI:
10.2217/14622416.9.12.1825
PubMed ID:
19072641
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/19072641
Type:
Article
Language:
en
ISSN:
1744-8042
Appears in Collections:
Cell and Cryobiology Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorPaige, Adam J.W.en_GB
dc.contributor.authorBrown, Roberten_GB
dc.date.accessioned2012-06-14T11:37:51Z-
dc.date.available2012-06-14T11:37:51Z-
dc.date.issued2008-12-
dc.identifier.citationPharmaco(epi)genomics in ovarian cancer. 2008, 9 (12):1825-1834 Pharmacogenomicsen_GB
dc.identifier.issn1744-8042-
dc.identifier.pmid19072641-
dc.identifier.doi10.2217/14622416.9.12.1825-
dc.identifier.urihttp://hdl.handle.net/10547/228927-
dc.description.abstractOvarian cancer shows considerable variability in its chemoresponse, however, the prospect of individualized medicine holds high hopes for improving patient survival. The influence of interindividual genomic polymorphisms on drug response (pharmacogenomics) is well established, and a variety of candidate loci in ovarian tumors have been identified, including ERCC1, ABCB1 and p53 variants. Recently pharmacoepigenomic modulators of key genes and pathways, such as promoter methylation (MLH1 and BRCA1 genes) and microRNA regulation (PTEN/AKT and NF-kappaB pathways) have been implicated in ovarian cancer chemoresponse. Epigenomic studies have until now mainly focused on tumor-specific changes, although germ-line epigenetic change may also be of importance. However, assessing the relevance of these potential pharmaco(epi)genomic biomarkers in clinical trials requires well powered studies in homogeneous populations, with independent validation sets, to distinguish real associations from false-positives. In addition, the selection of one gene or locus as having sufficient phenotypic effect to impact on clinical outcome may be an oversimplification. Integrated approaches that identify stable pharmacogenomic and epigenomic patterns and their relationship with expression patterns and gene function will be increasingly necessary.en_GB
dc.language.isoenen
dc.publisherFuture Medicineen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/19072641en_GB
dc.rightsArchived with thanks to Pharmacogenomicsen_GB
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEpigenesis, Genetic-
dc.subject.meshFemale-
dc.subject.meshGenetic Markers-
dc.subject.meshHumans-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPharmacogenetics-
dc.titlePharmaco(epi)genomics in ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Imperial College, Hammersmith Hospital Campus, London W12 8EE, UK. a.paige@imperial.ac.uken_GB
dc.identifier.journalPharmacogenomicsen_GB

Related articles on PubMed

All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.